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Abstract
Background: Although the ezetimibe-statin combination has been
shown to reduce LDL cholesterol by 12% compared to a statin
alone, its effect on hard clinical endpoints such as mortality is less
certain. Prior trials evaluated this combination in highly select population groups, but impact on all- cause mortality in the general
population has not been reported.
Methods: A total of 3,827 subjects who were prescribed either a
statin (group 1) or the combination of statin with ezetimibe (group
2) between January 1st, 2005 and January 1st, 2008 were studied.
Socio-demographic and clinical variables and mortality records
were analyzed. Univariate and stepwise multivariate logistic regression analysis was performed to identify the impact of ezetimibe on all-cause mortality, controlling for patient characteristics,
selected cardiovascular diseases and risk factors, and medications.
Results: Group 1 (n = 2,909), and group 2 (n = 918) were similar in
regards to most demographic variables, 152 patients died from any
cause during the study period. There was no difference in all cause
mortality between the groups. Hypertension, higher HDL-C and
omega-3 fatty acid use were associated with ezetimibe use in this
cohort of patients and were considered as covariates in the analysis.
Patients on the drug combination did not experience lower mortality after controlling for covariates and other significant risk factors.
Conclusions: No significant mortality benefit was found with the
use of ezetimibe in combination with a statin over use of a statin
alone. Omega-3 fatty acid use and higher HDL-C demonstrated a
substantial survival benefit.
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Introduction
Ezetimibe is a cholesterol lowering medication that works
by blocking enteric and biliary absorption of cholesterol, although its exact mechanism of action and affect on various
other body systems related to atherosclerosis are under debate [1]. Approved in 2002, Ezetimibe in combination with a
statin has been shown to reduce LDL cholesterol ((LDL-C))
15% more compared to a statin taken alone [2]. Ezetimibe
as a monotherapy has been shown to reduce LDL-C by18
% when compared to a placebo [2, 3]. Because the association between LDL-cholesterol reduction and decreased cardiovascular risk has been clearly established, ezetimibe was
assumed to possess clinical efficacy and became routinely
prescribed [4].
Although the effectiveness of ezetimibe in lowering
cholesterol has been demonstrated in several studies, its
clinical efficacy has been called into question following the
ENHANCE trial (Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression) which
showed that there was no difference in the carotid intimamedia thickness in patients taking simvastatin and ezetimibe
compared to those on simvastatin alone, despite having reduced overall total cholesterol, LDL-C, triglycerides , and
C-reactive protein [5].
Other studies that followed yielded conflicting results
with SANDS (Stop Atherosclerosis in Native Diabetics
Study) and VYCTOR (Vytorin on Carotid Intima-Media
Thickness and Overall Arterial Rigidity) demonstrating a
reduction in carotid intima-media thickness. However the
ARBITER 6 HALTS trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol
6-HDL and LDL Treatment Strategies in Atherosclerosis)
showed no improvement in intima-media thickness with the
addition of ezetimibe. Further, the impact of ezetimibe on
hard clinical endpoints such as mortality and cardiovascular events has not been proven till date [6-8]. Two studies
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Figure l. Flowchart of cohort assembly.

(SEAS: Simvastatin and Ezetimibe in Aortic Stenosis, and
SHARP: Study of Heart and Renal Protection) that demonstrated reduction in major cardiovascular events involved
comparison of patients taking a combination of a statin plus
ezetimibe versus those taking a placebo alone [9, 10]. The
true clinical effect of ezetimibe can only be inferred by using
a comparison group that takes a statin alone.
We therefore conducted a retrospective cohort study to
compare differences in all-cause mortality between patients
taking ezetimibe and a statin, and those on monotherapy
with a statin alone.

Methods
A flowchart of cohort assembly can be found in Figure 1.
The University of Kansas Hospital Mid-America Cardiology
database of electronic patient medical records was used for
this study. The study was carried out after obtaining approval
from the human subjects committee and waiver of consent
for data retrieval.
All social, demographic and clinical variables were obtained from the electronic database. Baseline lipid values of
all patients on a statin prior to initiation of ezetimibe were
276

also retrieved.
Study population; Patients who were not diagnosed with
dyslipidemia were excluded, and only patients who were
prescribed a statin were included. Patients taking combination ezetimibe and a statin (group 1) were compared to those
prescribed only a statin (group 2). In order to account for differences in prescribing patterns due to the novelty of ezetimibe, patients who were prescribed either medication before
January 1st 2005 were excluded. There was a dramatic fall
in ezetimibe prescriptions after articles with negative and inconclusive findings were published, therefore new prescriptions after January 1st, 2008 were also excluded [5].
Follow-up: All patients were followed until January
2009. Patients who were on either medication for at least 1
year and died during this time period were noted.
Endpoint
The study’s primary endpoint was all cause mortality.
Statistical analysis
Continuous variables between the groups were compared using unpaired t tests or Wilcoxon two-sample tests depending
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Table 1. Characteristics of Ezetimibe Plus Statin Versus Statin Only Patients
Characteristic

Statin and Ezetimibe (n = 918)

Statin only (n = 2,909)

P-value

Gender (Male)

517 (56%)

1,596 (55%)

0.447

Age

62.1 ± 11.5

63.6 ± 12.3

0.001

BMI

31.5 ± 6.9

31.2 ± 7.6

0.413

Weight

203.7 ± 50.8

200.7 ± 51.3

0.119

History of Tobacco use

517 (56%)

1,636 (56%)

0.970

Cholesterol

170.1 ± 62.3

169.6 ± 46.3

0.785

LDL-C

96.2 ± 42.1

96.6 ± 40.3

0.116

HDL-C

47.1 ± 13.3

48.2 ± 14.4

0.050

Hypertension

600 (65%)

2,051 (71%)

0.004

Coronary Artery Disease

405 (44%)

1,027 (35%)

< 0.001

Diabetes

250 (27%)

838 (29%)

0.378

Myocardial Infarction

47 (5%)

160 (6%)

0.738

CABG

60 (7%)

131 (5%)

0.019

PCI

91 (10%)

245 (8%)

0.181

Cerebrovascular Accident

42 (5%)

161 (6%)

0.273

Transient Ischemia Attack

34 (4%)

120 (4%)

0.630

Death

35 (4%)

117 (4%)

0.652

Beta-blocker

605 (66%)

1,838 (63%)

0.145

ACE-I

473 (52%)

1,584 (54%)

0.129

ARB

185 (20%)

547 (19%)

0.361

Omega-3

378 (41%)

935 (32%)

< 0.001

Aspirin

722 (79%)

2,165 (74%)

0.009

Diuretic

411 (45%)

1,319 (45%)

0.790

ACE-I: angiotensin converting enzyme inhibitor; ARB: angiotensin II receptor blocker; BMI: body mass index; CABG:
coronary artery bypass graft; HDL-C: high density lipoprotein cholesterol; LDL-C: low density lipoprotein cholesterol;
PCI: percutaneous coronary intervention.

on whether the variables were normally distributed, and categorical variables were compared using two-sided chi square
tests. Characteristics between patients prescribed or not prescribed ezetimibe are compared using the same methods.
Odds ratios were calculated using logistic regression and
95% confidence intervals. Logistic regression modeling was
done to determine whether measured variables predicted if a
patient had greater odds of being prescribed ezetimibe, and
stepwise logistic regression was used to determine the opti-

mal model. Odds of mortality were then calculated for each
variable using logistic regression. All variables were put into
a full model to control for confounding, and stepwise regression was used to determine the optimal model Statistical
analysis of the data was performed using SAS version 9.1.3
(SAS Inc, North Carolina, USA). Statistical significance was
considered present when P < 0.05.
The authors of this manuscript have certified that they
comply with the Principles of Ethical Publishing in the Inter-
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Table 2. Odds of Being Prescribed Ezetimibe
Characteristic

Unadjusted Odds Ratio

Stepwise Model

HDL-C

0.994 (0.989 - 0.999)

0.992 (0.985 - 1.000)

Hypertension

0.805 (0.705 - 0.919)

0.758 (0.609 - 0.942)

Omega-3 fatty acids

1.689 (1.483 - 1.923)

1.457 (1.178 - 1.802)

HDL-C: high density lipoprotein cholesterol.

national Journal of Cardiology [11].

Results
There were some significant differences between the groups
(Table 1). The ezetimibe plus statin group was younger (P <
0.001) and had lower HDL-C levels (P = 0.050) with higher
incidence of coronary artery disease (P < 0.001) and CABG
procedures (P = 0.019) in comparison to the statin only
group. Hypertension was more prevalent in the statin-only
group (P = 0.004). There was no difference between the total
cholesterol (P = 0.785) or LDL (P = 0.116) between the two
groups at baseline.
Logistic regression was used to determine whether certain characteristics increased the odds of a patient being prescribed ezetimibe (Table 2). Using stepwise regression, three
variables significantly changed the odds. Patients with higher HDL levels had lower odds of being on ezetimibe in addition to a statin. Patients diagnosed with hypertension were
19.5% less likely to be on both medications, and those taking
omega-3 were 69% more likely to be taking ezetimibe.
The odds of mortality based on the measured demographic variables, cholesterol levels, disease diagnoses,
cardiovascular procedures, and cardiovascular medications
were each calculated independently using logistic regression
(Table 3). No survival advantage was seen with ezetimibe
added to a statin (4% in both groups). When controlling for
all measured factors, advancing age, a history of smoking,
hypertension, a lower HDL level, having diabetes, taking
beta-blockers, taking diuretics, and not taking omega-3 fatty
acids were all significantly associated with mortality. Ezetimibe dropped out of the final model and was then added
back to find a final odds ratio. As could be predicted from
looking at Table 1, a patient who takes both ezetimibe and
statins was not found to benefit with regard to all cause mortality from a patient taking only statins (OR 1.067, 95% CI:
0.713 - 1.598). Omega-3 fatty acid use (OR 0.554, 95% CI:
0.373 - 0.823) or a higher HDL-C (OR 0.974, 95% CI: 0.959
- 0.989) emerged as significantly protective of all cause mortality.
278

Discussion
This study adds to the growing body of evidence that ezetimibe may not provide substantial outcomes benefit in the
treatment of hyperlipidemia. Our data indicate that there is
no apparent mortality benefit for ezetimibe over mid-term
follow up after one to three years of use.
Two trials where ezetimibe has been shown to have
clinical efficacy are the SEARS and the SHARP trial. In the
SEAS trial (Simvastatin and Ezetimibe in Aortic Stenosis)
which compared patients on simvastatin 40 mg and ezetimibe 10 mg to those on placebo, fatal and nonfatal myocardial infarctions were significantly reduced with associated
reductions in LDL-C. The SHARP trial demonstrated a 17%
reduction in major atherosclerotic events. However, both
these trials involve use of a statin and ezetimibe in comparison with a placebo and the observed clinical benefits could be
due to the statin alone [9, 10]. In contrast our study compares
the mortality benefit in patients taking statin and ezetimibe
against those taking statin alone. To our knowledge ours is
the first study that attempts to look at the clinical efficacy of
ezetimibe in comparison to a statin alone and demonstrated
no additive benefit for using ezetimibe.
Ezetimibe works by inhibiting the cholesterol absorption in the jejunum while statins work by inhibiting cholesterol synthesis by inhibiting the enzyme HMG CoA reductase [12]. Reduced hepatic synthesis of LDL-C by the statins
results in up regulation of hepatic LDL receptors and consequent increase in uptake of LDL-C from the blood resulting
in reduced serum LDL levels [13]. However, these effects
also result in enhanced cholesterol absorption. Thus ezetimibe which acts by inhibiting cholesterol absorption in the
jejunum is supposed to have a complementary mechanism
of action to that of the statins and the combination has been
shown to achieve LDL-C reductions that have not been possible with statin monotherapy alone. However, these reductions in LDL-C have failed to demonstrate clinical benefits
as seen in the ENHANCE and the ARBITER 6 HALTS trials [5, 8]. Thus the randomized control trial (IMPROVE IT)
which is testing clinical events in acute coronary syndrome
patients on ezetimibe in addition to intensive statin treatment
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Table 3. Odds of Mortality Based on Cardiovascular Risk Factors
Characteristic

Unadjusted Odds Ratio

Adjusted Odds Ratio

Stepwise Model

Gender (Male)

1.329 (0.952 - 1.856)

1.041 (0.672 - 1.613)

-

Age

1.063 (1.046 - 1.080)

1.066 (1.050 - 1.083)

1.059 (1.042 - 1.077)

BMI

0.993 (0.953 - 1.034)

0.979 (0.933 - 1.026)

-

Weight

0.995 (0.989 - 1.001)

0.999 (0.992 - 1.007)

-

History of Smoking

1.956 (1.370 - 2.794)

1.929 (1.337 - 2.784)

1.884 (1.303 - 2.725)

Cholesterol

0.992 (0.986 - 0.997)

0.995 (0.989 - 1.001)

-

LDL-C

1.004 (0.999 - 1.009)

1.006 (1.001 - 1.010)

1.005 (1.001 - 1.010)

HDL-C

0.969 (0.955 - 0.984)

0.976 (0.960 - 0.992)

0.974 (0.959 - 0.989)

Hypertension

1.057 (0.741 - 1.508)

0.643 (0.435 - 0.951)

0.840 (0.583 - 1.211)*

Coronary Artery Disease

2.074 (1.497 - 2.874)

1.308 (0.878 - 1.948)

-

Diabetes

2.490 (1.797 - 3.450)

2.319 (1.653 - 3.252)

2.535 (1.773 - 3.624)

Myocardial Infarction

1.105 (0.555 - 2.200)

0.858 (0.412 - 1.788)

-

CABG

3.719 (1.624 - 4.552)

1.501 (0.847 - 2.659)

-

PCI

0.971 (0.544 - 1.733)

0.844 (0.448 - 1.591)

-

CVA

3.194 (1.281 - 3.760)

1.197 (0.673 - 2.126)

-

TIA

1.737 (0.890 - 3.350)

1.536 (0.767 - 3.077)

-

Beta-blocker

2.274 (1.524 - 3.394)

1.676 (1.109 - 2.535)

1.625 (1.064 - 2.482)

ACE-I

1.543 (1.102 - 2.162)

1.040 (0.712 - 1.519)

-

ARB

1.328 (0.906 - 1.948)

1.149 (0.760 - 1.737)

-

Omega-3

0.561 (0.382 - 0.823)

0.547 (0.369 - 0.811)

0.554 (0.373 - 0.823)

Aspirin

1.231 (0.827 - 1.830)

0.841 (0.546 - 1.295)

-

Diuretic

2.020 (1.447 - 2.820)

1.407 (0.961 - 2.059)

1.461 (1.011 - 2.112)

Ezetimibe

0.946 (0.644 - 1.390)

1.093 (0.733 - 1.628)

1.067 (0.713 1.598)**

ACE-I: angiotensin converting enzyme inhibitor; ARB: angiotensin II receptor blocker; BMI: body mass index; CABG: coronary
artery bypass graft; CVA: cerebrovascular accident; HDL-C: high density lipoprotein cholesterol; LDL-C: low density lipoprotein cholesterol; PCI: percutaneous coronary intervention; TIA: transient ischemia attack; *Hypertension was added back into
the model to control confounding; **Ezetimibe was added back into the stepwise model because it drops out. P values < 0.05
for all odds ratios by stepwise model except * and **.

is highly anticipated.
Limitations: Though this study indicates a lack of clinical efficacy for ezetimibe, it does face several limitations.
Despite the large sample size, the data only comes from one
group of cardiologists at one medical center and is retro-

spective. Our study did not include lipid values following
administration of ezetimibe. Thus the benefits of LDL reduction could not be demonstrated in our study. However the
primary aim was to look at the clinical endpoint of mortality
as LDL reduction by ezetimibe has already been well estab-
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lished.
Conclusion

5.

No significant mortality benefit was found with the use of
ezetimibe in combination with a statin. Further randomized
trials investigating the clinical efficacy of ezetimibe in the
general population are needed.
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